 CURRICULUM VITAE Cardiology Practice and Heart Center at the Isar, Munich, Germany |
|
| Date of birth: | May11th 1949 in Passau, Bavaria, Germany |
| Citizenship: | Germany |
| Family Status: | Married since 1972, two children |
|
|
|
| 1968 | B.S.-equivalent (Abitur at Rupprecht-Gymnasium, Munich, Germany) |
| 1968 - 1974 | Medical School at the University of Munich (Ludwig-Maximilians-University, LMU) |
| 1970 - 1974 | Research Associate Institute for Experimental Cardiovascular Pharmacology, University of Munich |
| 1975 | Thesis (MD), Dissertation, Institute for Experimental Cardiovascular Pharmacology, University of Munich, Topic: "Effects of Aescin on the Circulation of the Cat", Magna cum Laude |
| 1974-1975 |
|
| 1975 - 1982 |
|
| 1982 - 1986 |
|
| 1982 - 1986 |
|
| 1982 - 1986 |
|
| 1982 - 1986 |
|
| 1986 | PhD-equivalent Thesis, („Habilitation“) at the Ludwig-Maximilians-University, Munich (Prof. Dr. med. E. Buchborn) Topic: "Nitrate Tolerance: Induction, Rational Circumvention and Consequences for a Combination Therapy" |
| 1987 - 1989 |
|
| 1987 - 1989 |
|
| 1990 | Attending physician, Cardiology Associates at the Red Cross Hospital, Frankfurt/Main, Germany |
| 1990 |
|
| 1996 |
|
| 1998 | Full Professor of Medicine at the Ludwig-Maximilians-University (LMU), Munich |
| Today | Private practice since 1991 (all insurances), Cardiology Associates in Munich and Director, Heart Center at the Isar, Munich |
|
|
|
|
|
| 1974 | ECFMG #2254209 (for USA Medical License) |
| 1975 | General Medical License (Germany) |
| 1981 | Subspecialty Board of Nuclear Cardiology |
| 1984 | Board of Internal Medicine (Germany) |
| 1984 | Board of Cardiology (Germany) |
| 2003 | Board of Endovascular Radiation Therapy (Germany) |
|
|
|
| American College of Cardiology (ACC) | |
| American Heart Association (AHA), Council of Clinical Cardiology, Professional Member | |
| American Society of Nuclear Cardiology (ASNC) | |
| Bavarian Society of Cardiologists in Private Practice (BFK), founding member | |
| European Council of Cardiology Practice (ECCP), founding member | |
| European Society of Cardiology (ESC) | |
| German Society of Cardiology and Cardiovascular Research (DGK) | |
| European Council of Cardiology Practice (ECCP) | |
| German Society of Internal Medicine (BDI) | |
| German Society of Interventional Cardiology (BIK), founding member | |
| Working Group for Interventional Cardiology of the German Society of Cardiology (DGK) | |
| Working Group for Nuclear Cardiology of the German Society of Cardiology (DGK) | |
| Working Group for Cardio-CT of the German Society fof Cardiology (DGK) | |
|
|
|
| FESC (Fellow of the European Society of Cardiology) | |
| FACC (Fellow of the American College of Cardiology) | |
| FAHA (Fellow of the American Heart Association) | |
|
|
|
| President, Bavarian Society of Cardiologists in Private Practice (BFK) | |
| Executive Board, German Society of Interventional Cardiology (BIK) | |
| Executive Board, Quality Control of Invasive Procedures in Bavaria (BAQ) | |
| Appointed Expert for Disease Management Programs (DMP) for CAD in Germany | |
| Appointed Expert for National Guidelines for Chronic CAD in Germany | |
| Member of the Nucleus of the Working Group „Cardiac CT“ of the DGK | |
| President, Annual Symposium of p-c-i live in Munich | |
| Associate Director, TCT | |
| Editorial Board, EuroIntervention Journal | |
| Editorial Board, Clinical Research in Cardiology Journal | |
| Editor-in-Chief of the bilingual Journal „CCN“ (Cathlab and Cardiovascular News) | |
|
|
|
| Chairman, PCI Guidelines of the European Society of Cardiology (ESC) | |
| President, German Society of Cardiologists in Private Practice (BNK) | |
| Vice President, German Society of Interventional Cardiology (BIK) | |
| Chairman, Working Group of Interventional Cardiology (DGK) | |
| Chairman, Working Group of Intracoronary Brachytherapy (DGK) | |
| Member of the Committee for Practice Guidelines and Policy Conference of the ESC | |
| Member of the Guideline Committee of the German Cardiac Society (DGK) | |
| Treasurer of the Board, European Council of Cardiology Practice (ECCP) | |
| Member of the 3rd Task Force of the ESC for the Prevention of Cardiovascular Diseases | |
| Member of the ESC Task Force for Implementation of the Guidelines for the Management of Heart Attacks | |
PREVIOUS HONORABLE FUNCTIONS and ELECTED POSITIONS: |
|
| Chairman, PCI Guidelines of the European Society of Cardiology (ESC) | |
| President, German Society of Cardiologists in Private Practice (BNK) | |
| Vice President, German Society of Interventional Cardiology (BIK) | |
| Chairman, Working Group of Interventional Cardiology (DGK) | |
| Chairman, Working Group of Intracoronary Brachytherapy (DGK) | |
| Member of the Committee for Practice Guidelines and Policy Conference of the ESC | |
| Member of the Guideline Committee of the German Cardiac Society (DGK) | |
| Treasurer of the Board, European Council of Cardiology Practice (ECCP) | |
| Member of the 3rd Task Force of the ESC for the Prevention of Cardiovascular Diseases | |
| Member of the ESC Task Force for Implementation of the Guidelines for the Management of Heart Attacks | |
EDITORIAL CONSULTANT for PEER-REVIEWED JOURNALS: |
|
| American Heart Journal | |
| American Journal of Cardiology | |
| American Journal of Medicine | |
| Catheterization and Cardiovascular Intervention | |
| Circulation | |
| Clinical Cardiology | |
| Clinical Research in Cardiology | |
| Deutsche Medizinische Wochenschrift | |
| EuroIntervention | |
| European Heart Journal | |
| Heart | |
| International Journal of Cardiology | |
| JACC | |
| JAMA | |
| Lancet | |
|
|
|
| A.A.C.H.E.N. (Angiotensin-II Antagonist to reduce post Coronary stent Hyperplasia of Endothelial Neointima) | |
| ACUITY (A randomized comparison of bivalirudin vs. heparin and GP IIb/IIIa inhibitors in patients undergoing early invasive management for NSTE-ACS) | |
| ARTIST (Angioplasty vs. Rotablation for In-Stent restenosis) | |
| BETA-CATH (Beta Cath System Study for brachytherapy of de-novo coronary lesions) | |
| BRIE (Beta Radiation In Europe), Principal Investigator for Germany | |
| CAST (Cardiac Arrythmia Supression Trial) | |
| CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilization) | |
| CYPHER (German Registry for prospective Evaluation and Follow-up of Patients after Cypher Stent Implantation) | |
| DaVINCI (Registry for prospective Evaluation and Follow-up of Patients after Vision Stent Implantation) | |
| DES.DE (German Drug-Eluting Stent Registry), Member of the Steering Committee | |
| DETECT (Diabetes Cardiovaskular Risk-Evaluation), Member of the Steering Committee | |
| DUETT (A Novel Vascular Sealing Device for Closure of Percutaneous Arterial Access Sites), Principal Investigator | |
| EBEAT (Electron Beam Computed Tomography assessment of coronary calcification), Member of the Safety/Endpoint Committee (SEC) | |
| ENDEAVOR II (Randomized, controlled trial to Evaluate the AVE ABT-578 Eluting Driver Sten) | |
| EURO HEART SURVEY (A prospective Registry Study of the European Society of Cardiology) | |
| EUROSTAR II (European prospective study of the COSTAR Paclitaxel-Eluting Coronary Stent System as compared to the bare stent), Principal Investigator | |
| EVIDENT (Endovascular Investigation Determining the safety of new Tacrolimus-eluting stent grafts) | |
| EVOLVE-II (Randomized Evaluation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent), Principal National Investigator | |
| EXPRESS (International Registry for prospective Evaluation of patients after EXPRESS Stent Implantation), Principal Investigator | |
| HEALING II + IIb (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth: Progenitor Endothelial Cells) | |
| IMPULSE (Impact Upon Long lesion Stenting) | |
| ISAR-PROJECT-2 (Clinical Evaluation of on-site coating with two Rapamycin dose regimes) | |
| IST (Intracoronary Radiation Therapy), Principal Investigator | |
| IT Biodegradable Study (The Biodegradable Poly-L-Lactic Acid Igaki-Tamai Coronary Stent), Principal Investigator | |
| LUNAR ROX (Registry for prospective Evaluation of Patients after Lunar Rox Stent Implantation), Principal Investigator | |
| LUSTY (Lunar Stent study), Principal Investigator | |
| MASTER (The MGuard mesh-based Embolic Protection Stent for Acute ST-Elevation Reperfusion Trial), Co-Principal Investigator | |
| MUNICH (Multislice Normal Incidence of Coronary Health), Principal Investigator | |
| NOBORI-1 (Prospective, Randomized, Multi-Center Comparison of the Nobori and Taxus Drug Eluting Stent System), Member of the Steering Committee | |
| NIRTOP ('Fused-Gold' vs. 'Bare' Stainless Steel NIRflex Stents), Member of the Steering Committee | |
| NUGGET (Nir Ultimate Gold-Gilded Equivalency Trial) | |
| OPEN II (Assessment of the STENTYS Paclitaxel-eluting selfexpanding stent in coronary bifurcation lesions) | |
| PETN (Pentaerythrityltetranitrate Evaluation of Tolerance to Nitrates), Principal Investigator | |
| PLATINUM PLUS (Randomized Multicenter Trial to Assess the Everolimus-Eluting Coronary Stent System), Co-Principal Investigator | |
| RECALL (Heinz Nixdorf Recall Study), Advisory Board | |
| REMEDEE (Randomized Study to Evaluate the Combo Abluminal Sirolimus Coated Bio-Engineered Stent) | |
| RENO (Multicentre European Registry of intraluminal coronary Beta Brachytherapy) | |
| RESCUT (Restenosis Cutting Balloon Evaluation) | |
| RESOLUTE-AC (All-Comers Randomized Comparison of a Zotarolimus-Eluting Stent with an Everolimus-Eluting Stent for PCI), Co-Principal Investigator | |
| REVEAL HPS 3 / TIMI 55 (Randomized Evaluation of Anacetrapib in pats. with established vascular disease for increasing HDL-Cholesterol) | |
| SAFE (A global post-market surveillance for the Dexamethason eluting Stent) | |
| SCORE (Study to compare restenosis rate of the Quanam 7-hexanoyltaxol-eluting stent) | |
| SEAL (Safe and Effective Arterial Closure) | |
| START (Stents and Radiation Therapy) | |
| TAXUS-I (Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions) | |
| TAXUS-II (Randomized Study of Slow- or Moderate-Release Polymer-Based Paclitaxel-Eluting Stents) | |
| TAXUS-VI (Randomized, double-blind study to assess paclitaxel-eluting stents in the treatment of longer lesions) | |
| OLYMPIA (Global TAXUS Liberté Registry) | |
| ZOMAXX I (Randomized Evaluation of the Zomaxx ABT 578-eluting stent compared to the Taxus Express Paclitaxel-Eluting Stent) | |
|
|
|
| Over 200 full publications in peer-reviewed journals and many book chapters, please see separate file. | |
